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Background: Angiogenesis represents a highly multi-factorial and multi-cellular complex (patho-) physiologic event
involving endothelial cells, tumor cells in malignant conditions, as well as bone marrow derived cells and stromal
cells. One main driver is vascular endothelial growth factor (VEGFA), which is known to interact with endothelial
cells as a survival and mitogenic signal. The role of VEGFA on tumor cells and /or tumor stromal cell interaction is
less clear. Condition specific (e.g. hypoxia) or tumor specific expression of VEGFA, VEGF receptors and co-receptors
on tumor cells has been reported, in addition to the expression on the endothelium. This suggests a potential
paracrine/autocrine loop that could affect changes specific to tumor cells.
Methods: We used the monoclonal antibody against VEGFA, bevacizumab, in various in vitro experiments using cell
lines derived from different tumor entities (non small cell lung cancer (NSCLC), colorectal cancer (CRC), breast
cancer (BC) and renal cell carcinoma (RCC)) in order to determine if potential VEGFA signaling could be blocked in
tumor cells. The experiments were done under hypoxia, a major inducer of VEGFA and angiogenesis, in an attempt
to mimic the physiological tumor condition. Known VEGFA induced endothelial biological responses such as
proliferation, migration, survival and gene expression changes were evaluated.
Results: Our study was able to demonstrate expression of VEGF receptors on tumor cells as well as hypoxia
regulated angiogenic gene expression. In addition, there was a cell line specific effect in tumor cells by VEGFA
blockade with bevacizumab in terms of proliferation; however overall, there was a limited measurable consequence
of bevacizumab therapy detected by migration and survival.
Conclusion: The present study showed in a variety of in vitro experiments with several tumor cell lines from
different tumor origins, that by blocking VEGFA with bevacizumab, there was a limited autocrine or cell-
autonomous function of VEGFA signaling in tumor cells, when evaluating VEGFA induced downstream outputs
known in endothelial cells.
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Tumor cells are dependent on consistent oxygen and
nutrient supply to promote tumor progression. Tumor
cells co-opt new vessels from the existing host vascular
network, driving tumor growth and the opportunity for
metastatic spread [1].
Most solid tumors develop regions of low oxygen ten-
sion because of a tissue imbalance between oxygen supply
and consumption [2]. Hypoxia inducible factor 1 (HIF-1)
is one of the most important transcription factors of the* Correspondence: Shannon.graver@biozentrum.uni-wuerzburg.de
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multitude of biological processes including cell prolifer-
ation, cell migration, metabolism, apoptosis and angio-
genesis. It thus acts on both the adaptation of affected
cells and the improvement of their vascular supply. A
well-studied hypoxia response in tumor cells is the pro-
duction of growth factors that induce angiogenesis [3].
HIF-1 activates transcription of vascular endothelial
growth factor (VEGFA), a major inducer of tumor
angiogenesis. Signaling through its receptors VEGFR1
(FLT-1), VEGFR2 (FLK-1) and co-receptor Neuropilin1
(NRP1) on endothelia represents the best characterized
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theory of targeting angiogenesis as a novel cancer ther-
apy [5], anti-angiogenic treatment has found its way into
clinical practice. The first approved therapeutic agent to
specifically target the tumor associated vessels of solid
tumors was bevacizumab, a monoclonal antibody against
all isoforms of VEGFA [6].
Bevacizumab has proven efficacy combined with
chemotherapy (or interferon in RCC) in clinical trials for
metastatic colorectal cancer (CRC), non-small cell lung
cancer (NSCLC), renal cell carcinoma (RCC) and meta-
static breast cancer (BC) (reviewed in [7]) and received
subsequent regulatory approval. The findings of many
clinical trials and case studies detect an increase in re-
sponse rates with the use of bevacizumab and/or a
prolonged time until disease progression. However the
impact on overall survival is more sporadic and not well
defined.
Factors influencing response to bevacizumab treat-
ment have been sought by the investigation of bio-
markers to improve patient stratification (reviewed in
[8]). One of the main pathways under investigation has
been the VEGFA pathway itself. VEGFA acts on endo-
thelial cells through its main receptor, VEGFR2, and is
expressed at high levels at sites of neoangiogenesis in
solid tumors [9].
There has been no consensus in literature on the ex-
pression of VEGF receptors in tumor tissue, especially
whether they are found exclusively on endothelial cells
or if tumor cells also benefit from VEGFA signaling via
paracrine and/or autocrine signaling loops. While there
is ample evidence for VEGF receptor expression on
tumor vasculature [9,10], there are also several studies
that demonstrate receptor expression on tumor cells
themselves (NSCLC, CRC and BC) [11-21]. Inconsisten-
cies seen with the use of anti-angiogenic therapy, led to
the hypothesis that tumor cells may do more than just se-
crete a chemotactic agent for endothelial cells and may
also contribute to response indicators seen clinically.
To investigate the potential effects of the VEGFA path-
way in tumor cells, we employed a series of cell lines from
the well-established NCI-60 panel to study angiogenic
gene and protein expression. In addition, cellular re-
sponses were analyzed under both normoxia and hypoxia
with reduced serum concentration, either with or without
VEGFA blockade through bevacizumab. We showed that
VEGF receptors are expressed by tumor cells and not only
by endothelial cells, which highlights the prospect of
complex angiogenic pathway/signaling cross talk between
various cell types. By blocking a key regulator of the an-
giogenic pathway, VEGFA, our results did not show any
adverse effects in tumor cells nor did bevacizumab alter
the angiogenic potential of the VEGFA pathway in tumor
cells. A functional consequence could be detected by achange in proliferation for one cell line in addition to the
down regulation of Neuropilin 1 in other cell lines. How-
ever, neither altered migration nor VEGF receptor 1 or 2
and ligand regulation was seen as a result of bevacizumab
treatment.
Material and methods
Cell culture
Thirty human tumor cell lines selected from the NCI-60
panel (NSCLC: A549, EKVX, H226, H23, H460, H522,
HOP62, HOP92, LXFL529; CRC: COLO205, HCT-116,
HCT-15, HT-29, KM12, SW620; RCC: 786–0, A498,
ACHN, CAKI-1, RXF-393, RXF-631, SN12C, SN12K1,
TK-10, UO-31; BC: BT-549, HS-578 T, MDA-MB-231,
MDA-MB-468, T47D) were obtained from American
Type Culture Collection and cultured in RPMI-1640
supplemented with 10% FBS (PAN Biotech, Germany),
1% Glutamax (Gibco, Germany), 1% penicillin and 1%
streptomycin (PAA, Austria) as recommended by the
NCI-Frederick Cancer DCTD Tumor Cell Line Reposi-
tory. Cells were passaged at ≈ 80% confluency.
HUVECs (human umbilical vein endothelial cells, a
gift from A. Fischer, Mannheim as previously described
[22] or purchased from PromoCell, Germany) were cul-
tured in M199 medium (Sigma-Aldrich, Germany) with
10% FBS, 25 μg/ml heparin (Sigma-Aldrich, Germany),
50 μg/ml ECGS (Sigma-Aldrich, Germany) and 1%
Glutamax on plates pre-coated with 0.2% gelatin. Re-
duced culture medium did not contain ECGS and serum
concentration was reduced to 1% FBS.
Hypoxia experiments were performed at 1% O2 (Pro-Ox
controller, Biospherix, USA) under serum-reduced condi-
tions (NSCLC, CRC and RCC: 1% FBS; BC: 5% FBS).
Where indicated, 50 ng/ml recombinant human VEGFA
(Miltenyi Biotec, Germany) and 250 μg/ml bevacizumab
(Avastin, was provided by Roche, Switzerland), was added.
Cell proliferation assay
Cell proliferation was assessed for up to 96 hours using
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] staining (Sigma-Aldrich, Germany) as previ-
ously described [23].
Briefly, between 2 × 103 and 5 × 103 cells/well (cell
line/doubling time dependent) were seeded into 96 well
plates and incubated overnight to adhere. Medium was
then replaced by RPMI-1640 with reduced FBS and
bevacizumab or VEGFA at the concentrations indicated
(time point zero). After 24, 48, 72 or 96 hours in hyp-
oxia, MTT (5 mg/ml in PBS) was added and incubated
for 2 hours at 37°C. The supernatant was removed and
reaction products were solubilized for 1 h in 10% HCl,
0.1% NP-40 in isopropanol. Absorbance was measured
at 570 nm with a reference wavelength of 650 nm using
an ELISA reader (Sunrise Absorbance Reader Tecan,
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triplicate and results are an average of a minimum of
three biological repetitions.
Cell migration assay
Cell migration was measured using the in vitro scratch
assay as described previously [24]. Briefly, cells were grown
in 6 well plates to a confluent monolayer, then scraped in
a straight line using a sterile P200 pipet tip in triplicate. To
remove debris, cells were washed once with PBS. Medium
was changed to serum reduced +/− bevacizumab and cells
were incubated for up to 24 hours under hypoxia at 37°C.
Images of the scratch width were measured using ImageJ
software [25] at the same location after 6 and 24 hours of
incubation.
Cell lysis and immunoblot analysis
Cell pellets were lysed in lysis buffer (20 mM HEPES
(pH 7.8), 500 mM NaCl, 5 mM MgCl2, 5 mM KCl, 0.1%
sodium deoxycholate, 0.5% Nonidet-P40, 10 μg/ml
Leupeptin, 10 μg/ml Aprotinin, 1 mM PMSF (phenylmeth-
anesulphonylfluoride), 200 μM Na3VO4, 0.1 M NaF) for
up to 4 hours on ice. Protein was resolved by SDS-
polyacrylamide gel electrophoresis and analyzed by
immunoblotting. The following antibodies were purchased
from Santa Cruz Biotechnology (Heidelberg, Germany):
anti-VEGFR1 (Flt1) (C17) rabbit, 1:200; anti-Neuropilin1
(H-286) 1:200. VEGFR2 1:200 and beta-Actin 1:10000 were
purchased from Cell Signaling (MA, USA) Cleaved PARP
1:2000 was purchased from BD Bioscience (USA). Vinculin
1:10,000 was purchased from Sigma-Aldrich (Germany).
Protein regulation was determined by pixel intensity
variance using Carestream Molecular Imaging software
(v5.4.2) with Vinculin as an internal standard.
Reverse transcription and quantitative real-time PCR
Total RNA was extracted from subconfluent monolayers
using peqGOLD TriFast (PeqLab, Germany) according to
the manufacturer’s instructions. cDNA was transcribed
using 2 μg total RNA with the RevertAid First Strand
cDNA Synthesis Kit (Fermentas, Germany). cDNA was
amplified by RT-PCR using a two-step PCR program of
40 cycles, with denaturation at 95°C for 15 s, annealing
and extension at 60°C for 30 s and followed by a melting
curve from 50 to 95°C using a Mastercycler ep realplex
(Eppendorf, Germany). All primers were synthesized by
Sigma-Aldrich (HPRT: F:AAGATGGTCAAGGTCGCA
AG, R:GTCAAGGGCATATCCTACAACAA; VEGFA: F:
TACCTCCACCATGCCAAGTG, R:GCTGCGCTGATAG
ACATCCA, VEGFA189 F:TATAAGTCCTGGAGCGTTC
CC, R:CTCGGCTTGTCACATCTGC; VEGFA165: F:AGA
TAGAGCAAGACAAGAAAATCCC, R:CTCGGCTTGT
CACATCTGC,VEGFA121: F:GTGTGTGCCCACTGAGG
AG, R:GCCTCGGCTTGTCACATTT, VEGFR1: F:CTTCACCTGGACTGACAGCA, R:ACAGCTGGAATGGCAG
AAAC; VEGFR2: F:ACAACCAGACGGACAGTGGT, R:
AGTCAGGCTGGAGAATCTGG; NRP1: F:CAAAACCA
GCAGACCTGGAT, R:CATTATGCCAACAGGCACAG;
GLUT1: F:GCTTTGTGGCCTTCTTTGAA, R:CAGAAC
CAGGAGCACAGTGA). Relative quantification was done
using ΔΔCt measurements on SYBR Green based fluores-
cence readings with HPRT as a housekeeping gene. Mea-
surements were done in triplicate.
Flow cytometry
Protein expression of receptors on the tumor cell sur-
face was determined by flow cytometry. Cells were
harvested using Accutase solution (Sigma-Aldrich,
Germany) after 24 hours of normoxia, hypoxia and hyp-
oxia with bevacizumab treatment. Cells were labeled for
Neuropilin1 with CD304- and VEGFR2 with CD309-
APC conjugated antibodies (Miltenyi Biotec, Germany)
and measured by a BD FACS Canto II flow cytometer.
HUVEC were used as a control. Analysis was done
using FlowJo software (version 8.8.6) to determine the
percentages of positive cells. Results represent averaged
percentages from two biological repetitions.
Propidium iodide (Sigma-Aldrich, Germany) stained
cells were prepared by fixing the cells in 80% ice cold
ethanol for up to 48 hours. Cells were then washed with
PBS and resuspended and incubated for 30 minutes in
38 mM sodium citrate, 24 μg/ml RNase A and 54 μM
propidium iodide prior to FACS measurement.
Statistical analysis
Unpaired, two-tailed Student’s t-test was performed for
statistical analysis. A p-value of <0.05 was considered to
indicate a significant difference.
Results
Cell line selection
As VEGFA is thought to work primarily through activa-
tion of one of the known VEGF receptors VEGFR1,
VEGFR2 and co-receptor Neuropilin1, in general two
cell lines per tumor type were selected from the NCI-60
panel of solid tumors (NSCLC: H522, HOP62, CRC:
HCT-116, HT-29, KM12, BC: HS-578 T, MDA-MB-231
and one RCC: A498), according to high relative expres-
sion levels from publicly available microarray data [26],
published data and our own preliminary gene expression
data related to angiogenesis pathway genes. These cell
lines are also representative of most of the indications
where bevacizumab is approved for clinical use and has
shown variable efficacy in clinical practice.
Tumor cell expression of VEGF receptors
The protein levels of VEGFR1, VEGFR2 and Neuropilin1
expressed by tumor cells were determined by western
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without bevacizumab under hypoxic conditions for
24 hours were examined to determine if there is any regu-
lation of receptor expression compared to normoxic con-
ditions (Figure 1A). The two VEGFR2-specific bands were
detected on HUVECs, which was used as a positive con-
trol and present in four of the selected tumor cell lines,
H522, HOP62 (NSCLC), HCT-116 (CRC) and MDA-
MB-231 (BC). Changes in expression of VEGFR2 as re-
sult of hypoxia or bevacizumab treatment in tumor cells
were difficult to evaluate by western blot, so we there-
fore assessed transcript changes and localization by flow
cytometry. VEGFR1 showed clear expression shown by
two bands in all cell lines with the exception of H522
(NSCLC). Whilst hypoxia up regulated expression in
A498 (RCC) by 1.8-fold, bevacizumab treatment does
not appear to strongly regulate VEGFR1 in the other
VEGFR1-expressing cell lines. Interestingly, all cell lines
showed expression for Neuropilin1, albeit at varying
levels, and protein expression was not significantly al-
tered by either hypoxia or bevacizumab treatment.Cell surface expression of VEGF receptors
Although western blot analysis did not show any overall
change in expression, to determine if receptor localization
was affected by hypoxia or bevacizumab treatment, cell
surface localization of VEGFR2 and Neuropilin1 was eval-
uated by flow cytometry (Figure 1B and 1C and summa-
rized in Table 1). VEGFR1 localization was not analyzed,
as no suitable antibody for FACS analysis was available.
Although all cell lines showed Neuropilin1 protein ex-
pression to varying intensities, this did not necessarily
translate to cell surface expression, with no detectable
expression on H522, HCT-116, HT-29 or KM12.
Neuropilin1 was expressed on the cell surface at a high
level in one breast tumor cell line (MDA-MB-231),
followed by A498 (RCC). Expression was present to a
lesser degree in HOP62 (NSCLC) and HS-578 T (BC)
exhibiting approximately 10–15% of cells with receptors
at the cell surface.
In contrast to Neuropilin1, VEGFR2 expression was
more limited on the surface of tumor cells, in line with
western blot analysis. As expected endothelial cells
showed expression of VEGFR2 and only one tumor
cell line, MDA-MB-231 (BC), with high numbers of
VEGFR2 positive cells compared to the other tumor cell
lines. The other tumor cell lines that had VEGFR2 pro-
tein expression, H522, HOP62 and HCT-116, did not
show VEGFR2 on their surface with the percentages of
positive cells remaining below 10%. Treatment under
hypoxia or with bevacizumab did not influence any ob-
vious change in either Neuropilin1 or VEGFR2 mem-
brane expression.Analysis of hypoxic VEGFA induction in tumor cells
Activation of HIF-1 under hypoxia should lead to a var-
iety of gene expression changes, including induction of
VEGFA, which may preferentially trigger specific chan-
ges in tumor cells. To this end, cells were incubated
under normoxic and hypoxic conditions for 24 hours
and total VEGFA mRNA levels were measured by quan-
titative real-time PCR.
Most tumor cells reacted to the hypoxic environment
with the induction of either VEGFA or GLUT1mRNA after
24 hours of hypoxia exposure, however to variable degrees
within the different tumor entities (Figure 1D and 1E).
Three tumor cell lines had significant induction of VEGFA,
which did not exactly match the pattern of GLUT1 mRNA
where six cell lines showed significant induction. MDA-
MB-231 (BC) and A498 showed no transcriptional regula-
tion of the two classical hypoxia inducible genes whereas
KM12 (CRC) and H522 (NSCLC) demonstrated induction
of only GLUT1. HS-578 T (BC) responded to the hypoxic
environment with a 2.7-fold increase of VEGFA over the
normoxic control and 2.8-fold change for GLUT1 (p =
0.05). HOP62 (NSCLC) showed the highest induction of
VEGFA with up to 3-fold (p = 0.012) along all investigated
tumor cell lines. For the two colorectal tumor cell lines
HCT-116 and HT-29 (CRC) VEGFA was upregulated to a
similar extent under hypoxic conditions with 2.5-fold (p =
0.008) and 2.4-fold (p = 0.007) (Figure 1D). The change in
either GLUT1 and/or VEGFA expression documents the
adaptive responsiveness of some tumor cells to the hyp-
oxic environment, giving rise to the possibility of autocrine
or paracrine VEGFA stimulation in comparison to those
cell lines where no induction is evident.
Gene expression regulation upon bevacizumab treatment
An evaluation of the VEGF signaling molecules was
performed to determine if mRNA expression was al-
tered, which may not be apparent by the less sensitive
evaluation from protein analysis.
Analysis of the different VEGFA isoforms VEGFA121, -165
and -189 revealed no evident regulation in all investigated
tumor cell lines as well as in HUVECs after bevacizumab
treatment in hypoxia for 24 hours. rhVEGF stimulation of
HUVECs led to an increase in VEGFA isoform expression,
however this change was not significant (Figure 2A).
Consistent with the protein analysis, seven cell lines
showed VEGFR1 expression, however there was also no
marked change in mRNA levels along with the HUVEC
controls (Figure 2 showing only those cell lines with detect-
able expression). VEGFR1 was upregulated 2.1-fold in
HUVEC when treated with rhVEGF and showed the op-
posing downregulation of 1.9-fold after rhVEGF and
bevacizumab treatment, however downregulation remained
below the threshold of significance (Figure 2B). VEGFR2
was present in four of the cell lines and remained
Figure 1 (See legend on next page.)
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Figure 1 Expression of VEGF receptors and hypoxic VEGF mRNA induction in tumor cells. (A) Protein expression of VEGFR1, VEGFR2 and
NRP1 was determined in tumor cells and HUVECs under normoxia and after 24 hours of hypoxia with or without bevacizumab. Vinculin was used
as a loading control. (B) Cell surface expression of VEGFR2 and NRP1 as analyzed by flow cytometry. Unstained cells cultured under normoxic
conditions were used as a control. (C) Quantification of VEGFR2+ and NRP1+ cell surface expression. (D) Relative change of VEGFA mRNA
expression under hypoxia versus normoxic controls. (E) Relative change of GLUT1 mRNA expression under hypoxia versus normoxic controls.
n.d. = not done.
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hypoxia in all of the VEGFR2-expressing cell lines
(Figure 2D). For HUVECs a 2-fold upregulation of
VEGFR2 was detected after rhVEGF stimulation, but treat-
ment with rhVEGF and bevacizumab only led to a 1.2-fold
downregulation, similar to the degree of VEGFR2 regula-
tion in tumor cells.
The VEGFA co-receptor Neuropilin1 was significantly
decreased in HS-578 T (BC) by a 3-fold down regulation
(p = 0.02). The other breast cancer cell line, MDA-MB-231,
showed also a downregulation (1.7-fold), however it was
below the threshold of significance determined by a
2-fold regulation. HOP62 (NSCLC) and HCT-116
(CRC) demonstrated a downregulation of 1.9- and
1.6-fold after bevacizumab treatment, which also remained
below the threshold (Figure 2C). The downregulation
was not seen at protein level in either cell line, sug-
gesting perhaps stabilization of proteins or changes in
mRNA translation. The remaining cell lines did not ex-
hibit a characteristic pattern of expression or regulation
(Figure 2). Interestingly HUVECs, when treated with
rhVEGF, showed strong upregulation of Neuropilin1 and
the opposing downregulation when rhVEGF was inhibited
by bevacizumab, which is the same pattern of regulation
of NRP1 detected in HS-578 T (BC) (Figure 2C).
In summary, although there is a clear trend towards
inhibition of VEGFA induced changes of VEGFA related
genes in bevacizumab treated HUVECs, there was no
consistent impact on gene expression patterns across
the tumor cell lines. Bevacizumab did however signifi-
cantly alter the Neuropilin1 expression in HS-578 T
along with a clear trend of down regulation in HUVECs
and three other cell lines, however not to a significant
extent.Table 1 Protein and cell surface expression of VEGFR1, VEGFR
NSCLC
H522 HOP62 HCT-116
Protein expression VEGFR1 - + -
VEGFR2 + - +
NRP1 + + +
Cell surface expression VEGFR1 n.d. n.d. n.d.
VEGFR2 - - -
NRP1 - + -
+ = present in cell line, - = not present in cell line, n.d. = not done.Effects of bevacizumab on tumor cell survival
As VEGFA acts as a survival factor that can rescue endo-
thelial cells from apoptosis, blockade by bevacizumab may
have the potential to influence cell survival in tumor cells
by the same mechanism. The levels of cleaved PARP (Poly
[ADP-Ribose] Polymerase) protein (Figure 3A and 3B)
and sub G1 phase propidium iodide conjugated DNA of
tumor cell lines (Figure 3C) were taken as indicators of
apoptosis. In general, levels of apoptosis were relatively
low in all cell lines investigated and they were not further
enhanced by bevacizumab treatment under hypoxic condi-
tions with reduced FBS concentrations. Non-small cell
lung cancer cells, H522 and HOP62, interestingly showed
a decrease in cleaved PARP and sub G1 cells when treated
with bevacizumab, however beyond the criteria of signifi-
cance (p = 0.13 and p = 0.25 respectively). In contrast
A498 (RCC) and HS-578 T (BC) exhibited a minor in-
crease in apoptosis according to both cleaved PARP and
sub G1 levels. All other cell lines investigated did not show
differences after bevacizumab treatment when compared
to controls. The magnitude of the effects observed was
limited compared to control experiments where each cell
line was treated with 150 nM staurosporine for 24 hours
as a potent inducer of apoptosis, with a representative ex-
ample shown for cell line KM12 in Figure 3A.
Effects of bevacizumab on tumor cell proliferation
With at least one receptor present in the selected cell
lines and with the induction of VEGFA under hypoxic
conditions, the system was challenged in an effort to re-
veal an autocrine/paracrine function. Proliferation rates
were examined in reduced serum media under hypoxic
conditions for up to 96 hours, however overall no obvi-
ous change between treated and untreated cells was2 and NRP1
CRC RCC BC
HT-29 KM12 A498 HS-578 T MDA-MB-231 HUVEC
+ - + + + +
n.d. - - - + +
+ + + + + -
n.d. n.d. n.d. n.d. n.d. n.d.
- - - - + +
- - + + + -
Figure 2 Gene expression analysis in bevacizumab treated tumor cells. Change in relative expression of (A) VEGFA isoforms, (B) VEGFR1, (C)
NRP1 and (D) VEGFR2 in bevacizumab treated cells after 24 hours of hypoxia versus untreated hypoxic cells. Only cell lines with detectable
expression are included. * indicates HUVECs were in addition stimulated with rhVEGF in the absence of bevacizumab and normalized against
untreated controls.
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Most cell lines did not meet statistical significance
according to the student’s 2-tailed t-test, with the excep-
tion of HT-29 (CRC).
To determine if an anti-proliferative effect of bevaci-
zumab could be seen in a wider range of cell lines, the
analysis was further expanded to include a screen of
30 cell lines from the NCI-60 panel, using the main solid
tumor types for which bevacizumab is approved, NSCLC,
CRC, RCC and BC. With the exception of HT-29 (CRC)
and SW620 (CRC), which showed minor, but opposing
changes in proliferation after bevacizumab treatment, an
decrease and increase respectively, bevacizumab did not
appear to affect tumor cell proliferation. The HUVEC
controls did show inhibition of proliferation as expected
with bevacizumab (Figure 4B).
In parallel experiments, rhVEGF was added to FBS re-
duced media in an attempt to stimulate the VEGFA
dependent pathways in tumor cells (data not shown).This was however unsuccessful in increasing proliferation
rates, including those tumor cells that expressed the major
VEGFA signaling receptor VEGFR2 (H522, HOP62, HCT-
116, and MDA-MB-231). As a control, HUVECs in con-
trast did show enhanced VEGF dependent proliferation
(Figure 4B).
Tumor cell migration with bevacizumab treatment
VEGFA has been described as a chemo-attractant and
motility factor in endothelial cells, thus blockade of
VEGFA by bevacizumab could also influence the migra-
tory potential of tumor cells. Cell migration was assessed
by the in vitro scratch assay, with experiments per-
formed under hypoxic and serum reduced conditions for
all cell lines. Migration was checked after 6 or 24 hours,
for cell lines with rapid migration and less motile cell
lines respectively (Figure 4C). Migration was highly vari-
able amongst the tumor cell lines, from a complete lack
of motility in some colorectal cell lines (COLO205,
Figure 3 Tumor cell survival after bevacizumab treatment. (A, B) Levels of apoptosis were determined in bevacizumab treated cells after
48 hours by western blot analysis using an antibody against cleaved PARP. ß-Actin served as a loading control. As a positive control all cell lines
were treated with staurosporine (0.15 μM) for 24 hours to induce apoptosis, an example of KM12 (CRC) and HUVEC is shown. (C) Quantification
of cellular sub G1 fraction after 48 hours of bevacizumab treatment. Cells were stained with propidium iodide and analyzed by flow cytometry.
Averaged data from three experiments are shown.
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after 24 hours for five renal cell lines, one lung
(LXFL529) and one breast (BT-549) cancer cell line.
HUVECs demonstrated a clear dependence on VEGFA
for migration with enhanced motility of 1.7-fold, while
this effect was reversed by bevacizumab treatment in
keeping with previous studies (Figure 4D) [27]. However
treatment with bevacizumab was not able to influence
the migration of the tumor cells when compared to un-
treated cells.
Discussion
VEGFA is a well known and equally well characterized
survival factor for endothelial cells [28]. The effect of
VEGFA mediated or supported tumor cell proliferation,
as a direct effect of the cytokine, is less characterized or
established. In line with previous findings, our study
demonstrated and confirmed that some tumor cells do
harbor VEGF receptors [8,9,13,28,29]. This, coupled with
the induction of VEGFA by hypoxia, supports the hy-
pothesis of a possible paracrine or autocrine mechanismthat could be disrupted by blocking VEGFA signaling by
bevacizumab leading to a direct tumor effect.
It is known that hypoxia is a major regulator of both
VEGFA and its receptors [30], however, we found no
uniform regulation of receptors or ligands across all cell
lines analyzed by either hypoxia or bevacizumab treat-
ment at an mRNA transcript or protein level. Changes
detected by mRNA analysis, such as NRP1 down regula-
tion in HS-578 T (BC), were not translated into protein
changes, suggesting alternative regulatory mechanisms,
which may be a result of translational variations or post
translational modifications along the secretory pathway.
Neuropilin1, which serves as a VEGFA co-receptor,
showed some regulation under hypoxic conditions,
which is consistent with previous published studies
[31]. This effect was however, not uniform across our se-
lected cell lines. Of note, although all cell lines expressed
Neuropilin1, cell surface expression of Neuropilin1 appe-
ared to correlate with high co-expression of VEGFR1.
Neuropilin1 has been reported to modulate VEGFR1
signaling leading to enhanced migration and survival of
Figure 4 Tumor cell proliferation and migration analysis after bevacizumab treatment. (A, B) Proliferation of bevacizumab treated cells as
a percentage of control. Cells were cultured under hypoxia and serum starved conditions for 72 hours. For comparison HUVEC were stimulated
with rhVEGF and treated with bevacizumab. (C, D) Migration of bevacizumab treated versus untreated cells after 24 or 6 hours of hypoxia. HUVEC
were again treated with rhVEGF.
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four Neuropilin1/high-VEGFR1 expressing cell lines were
highly motile, but our migration analysis did not demon-
strate any effect of VEGFA depletion via bevacizumab
treatment nor in the extended cell line investigation. This
may be due to the possibility that migration is controlled
through alternative binding partners of VEGFR1, such as
VEGF-B or PlGF or apparent after extended bevacizumab
exposure for up to 3 month as reported in the study by
Fan et al. [33,34]. Migration of tumor cell lines was highly
variable and the migration potential was not altered with
bevacizumab treatment.
Moreover, tumor cell dependence on VEGFA as a sur-
vival factor was explored via the quantification of apop-
tosis by cleaved PARP and confirmed by FACS analysis,
which did not produce evidence that bevacizumab had
an effect on cellular survival. It has been shown that de-
pletion of VEGFA or VEGFR1 through knock-down ex-
periments can interfere with the autocrine feedback loop
and survival of tumor cells, but only where VEGFR1 ispresent at nuclear membranes and therefore inaccessible
to extracellular ligands or bevacizumab [35]. Our experi-
ments show that the use of a VEGFA targeted antibody
is not able to mimic this phenomenon in our cell lines
as there is no evidence of a significant increase in apop-
totic cells upon single agent treatment.
VEGFA stimulated proliferation induced by hypoxia
was not inhibited by bevacizumab treatment and rem-
ained more or less unchanged in most tumor cells ex-
cept HT-29 (CRC). The decrease in proliferation noted
in HT-29, could not be attributed to changes in VEGFA
related gene or protein regulation and may be related to
other downstream components of the HIF response [36].
Small molecule receptor tyrosine kinases targeted to the
VEGFA pathway in HT-29 xenografts have shown some
tumor cell effects in other studies suggesting this path-
way does play a critical role in cell survival, however per-
haps only clearly evident when there are multiple
receptor targets [37]. The lack of proliferation changes
in the other cell lines was consistent at each time point
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http://www.cancerci.com/content/13/1/94investigated with only minor decreases or increases. In
contrast, endothelial cells showed a significant decrease
in proliferation rate after bevacizumab treatment. There
has been some limited analysis of individual cell lines
treated with bevacizumab in the literature, overall con-
curring with our results of a lack of major effects on
proliferation, [38] or even a slight increase in prolifera-
tion when treated with bevacizumab alone [39].
The role of VEGFA in generating endothelial cell
changes is well established, with the inhibition of VEGFA
leading to changes in tumor vasculature [40]. However,
patient outcomes using bevacizumab have implied that
VEGFA antibodies may also differentially affect the tumor
cells or the tumor’s microenvironment. Even with inherent
difficulties of in vitro studies, our data suggest that tumor
cells themselves are not intrinsically affected in an adverse
manner by bevacizumab monotherapy based on the selec-
tion of assays performed. In addition, the angiogenic po-
tential mediated through the VEGFA pathway was not
significantly altered in the tumor cell lines. The effect be-
yond vasculature permeability, remodeling and pruning of
an anti-VEGFA based therapy, is likely to be a complex
interaction of tumor vasculature, tumor stroma, immune
cells as well as the tumor cells.
Conclusions
Bevacizumab was the first approved therapeutic agent
targeting blood vessels of tumors, which has shown effi-
cacy in suppression of tumor growth and direct evidence
of anti-vascular effects in human tumors. The present
study showed in a variety of in vitro experiments with sev-
eral tumor cell lines from different tumor origins, that
there was a limited measurable effect with bevacizumab
monotherapy when evaluating VEGFA induced down-
stream outputs known from endothelial cells.
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